Exhibit 99.1

ABN 82 010 975 612

Level 18

101 Collins Street, Melbourne

Victoria 3000 Australia

Telephone: + 61 7 3273 9133

Facsimile: + 61 7 3375 1168

http://www.tbgbio.com/public/

Investor Presentation

Melbourne, Australia, 16 May 2016. TBG Diagnostics Limited (formerly Progen Pharmaceuticals Ltd) (ASX: TDL, OTC: PGLA) (“the Company”) is this week making a series of presentations to potential investors in Australia.

The presentation contains details on the Company’s current situation and plans for future growth and development.

For further information, please refer to the attached presentation.

ENDS

For more information:

Blair Lucas

Company Secretary

+61 7 3273 9133

+61 403 358 638

This release contains forward-looking statements that are based on current management expectations. These statements may differ materially from actual future events or results due to certain risks and uncertainties, including without limitation, risks associated with drug development and manufacture, risks inherent in the extensive regulatory approval process mandated by, amongst others, the United States Food and Drug Administration and the Australian Therapeutic Goods Administration, delays in obtaining the necessary approvals for clinical testing, patient recruitment, delays in the conduct of clinical trials, market acceptance of PI-88, PG545, and other drugs, future capital needs, general economic conditions, and other risks and uncertainties detailed from time to time in the Company’s filings with the Australian Securities Exchange and the United States Securities and Exchange Commission. Moreover, there can be no assurance that others will not independently develop similar products or processes or design around patents owned or licensed by the Company, or that patents owned or licensed by the Company will provide meaningful protection or competitive advantages.

TBG Diagnostics Ltd 6-K